title: Diffuse interstitial lung disease linked to vandetanib.
authors: Pulmonology, Croix Rousse Hospital, Lyon, France. sylvie.ernesto01@chu-lyon.fr
authors: Sylvie
authors: S
authors: Ernesto
authors: Dominique
authors: D
authors: Arpin
authors: Pascale
authors: P
authors: Nesme
authors: Maurice
authors: M
authors: Pérol
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D018572:Disease-Free Survival; D004342:Drug Hypersensitivity / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D057915:Drug Substitution; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D013147:Spirometry; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors*
chemical_list: D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D040301:Vascular Endothelial Growth Factor Receptor-2; C452423:vandetanib